AF WPartners

CEO of AFW Partners, previously Chief Investment Officer of the OCIO division and Senior Strategist at Shinhan Securities, with experience in institutional capital management and macro investment strategy.

Managing Director previously with Goldman Sachs in Seoul and Bank of America Merrill Lynch in Hong Kong and New York, advising on cross-border M&A, IPOs and shareholder defense. Holds a B.A. in Political Science from Columbia University.

Director who previously worked at Kiwoom Securities, Seoul IR Network and Yuanta Securities, focusing on IPO execution, investor communications and institutional relationships.

Principal formerly with Lead Compass Investment focusing on early-stage and growth investments in healthcare, ICT and industrial tech; holds a Ph.D. in Chemical and Biological Engineering from Seoul National University.

Associate who previously led a research team at Theragen Bio working on NGS applications; brings biotech and healthcare IT expertise. Holds an M.S. in Biomedical Science from Yonsei University College of Medicine.

Associate previously an equity research analyst at Kiwoom Securities and at FnPricing covering alternative assets including private equity and infrastructure.

General Manager overseeing fund operations and administration, previously at Friend Investment Partners, Eugene Investment & Securities and Muirwoods Ventures.

Assistant Manager supporting fund operations and administration, previously at DB Financial Investment managing SPC liquidity and client asset administration.

Chief Compliance Officer overseeing internal controls and operations, previously spent 21 years at Mirae Asset Securities in executive leadership roles.

Manager supporting fund operations, previously at Xcell Therapeutics, DAWON and Magellan Technology Investment handling financial reporting, IPO preparation and policy-backed fund vehicles.